Rare-disease medical education presents challenges distinct from broader therapeutic areas, driven by low prevalence, concentrated expertise, prolonged diagnostic journeys, and limited familiarity among PCPs. At the same time, traditional specialist-centric CME and congress models are no longer sufficient to support a fragmented, multidisciplinary care ecosystem.
This benchmarking report examines how biopharma organizations are re-designing rare-disease education to extend beyond Centers of Excellence and specialists to more effectively engage PCPs—and even extending outreach to pharmacists, genetic counselors, and other contributors within the broader diagnostic ecosystem. Based on comparative industry data, the research evaluates accredited and non-accredited education models, high-performing channels and formats, and content approaches that balance scientific rigor with scalability and accessibility.
The report also explores the growing strategic role of MSLs, society partnerships, and emerging applications of analytics and AI to identify education gaps, prioritize high-need segments, and assess learning transfer. Through benchmarks, peer insights, and practical guidance, the report helps organizations strengthen rare-disease education strategies that enable earlier diagnosis, appropriate referral, and improved patient care.